Instruction for use: Pyrabutol

ATX code N02BB53 Aminofenazone in combination with other drugs other than psycholeptics

Pharmacological group

Other non-narcotic analgesics, including non-steroidal and other anti-inflammatory drugs

Nosological classification (ICD-10)

H20 Iridocyclitis

recurrent iritis, sympathetic iridocyclitis, Sluggish posterior uveitis, Sluggish posterior uveitis, Posterior uveitis, the posterior segment of the eye Iridocyclitis, Iridocyclitis and other uveitis, Irit, Keratoiridotsiklit, Acute iritis, uveitis, cycle of Acute iridocyclitis, Acute non-infectious uveitis

M05 Seropositive rheumatoid arthritis

Rheumatoid arthritis seropositive

M15-M19 Osteoarthritis

M16 Coxarthrosis [arthrosis of the hip joint]

Hip osteoarthritis

M25.5 Pain in the joint

Arthralgia, Pain syndrome in musculo-articular diseases, Pain syndrome in osteoarthritis, Pain syndrome in osteoarthritis, Pain syndrome in acute inflammatory diseases of the musculoskeletal system, Pain syndrome in chronic inflammatory diseases of the musculoskeletal system, Pain in the joints, Soreness of the joints, Soreness of joints in severe physical exertion, Painful inflammatory joint damage, Painful conditions of the musculoskeletal system, Painful joint conditions, Painful traumatic affection of joints, Pain in the musculoskeletal system, Pain in Shoulder Joints, Pain in the joints, Joint pain, Joint pain with injuries, Musculoskeletal pain, Pain with osteoarthritis, Pain in the pathology of the joints, Pain in rheumatoid arthritis, Pain in chronic degenerative bone diseases, Pain in chronic degenerative joint diseases, Bone-joint pain, Joint pain, Arthritic pain of rheumatic origin, Articular pain syndrome, Joint pain, Rheumatic pain, Rheumatic pains

M42 Osteochondrosis

Pain in spinal osteochondrosis, Cervical osteochondrosis, Radicular syndrome in osteochondrosis, intervertebral osteochondrosis, osteochondrosis, Osteochondrosis with radicular syndrome, Osteocondritis of the spine

M45 Ankylosing spondylitis

Ankylosing spondylarthrosis, Marie-Strumpel disease, Ankylosing spondylitis, Pain syndrome in acute inflammatory diseases of the musculoskeletal system, Pain syndrome in chronic inflammatory diseases of the musculoskeletal system, Bechterew's disease, Ankylosing spondylitis, Diseases of the spinal column, Rheumatic spondylitis, Bechterew-Marie-Strumpel disease

M77.9 Other unspecified

Capsule, Periarthritis, Tendonitis, Tendopathy, Periarthropathy

M79.0 Other unspecified rheumatism

Degenerative rheumatic disease, Degenerative and rheumatic diseases of the tendons, Degenerative rheumatic diseases, Localized forms of rheumatism of soft tissues, Rheumatism, Rheumatism with a pronounced allergic component, Rheumatism of the articular and extraarticular, Rheumatic attack, Rheumatic complaints, Rheumatic diseases, Rheumatic disease of the spine, Relapses of rheumatism, Articular and extra-articular rheumatism, Articular and muscular rheumatism, Articular rheumatism, Articular syndrome with rheumatism, Chronic rheumatic pain, Chronic articular rheumatism, Rheumatoid diseases, Rheumatic diseases of the intervertebral disc

R50 Fever of unknown origin

Malignant hyperthermia, Hyperthermia malignant

R52.2 Other constant pain

Pain syndrome, rheumatic origin, Pain at vertebral lesions, Pain in the chamber, Pain for burns, Pain syndrome weak or moderate, Perioperative pain,Moderate to severe pain, Moderately or weakly expressed pain syndrome, Moderate to severe pain, Ear pain of otitis, Neuropathic pain, neuropathic pain

R68.8 Other specified general symptoms and signs

Toxemia

Composition and form of release

1 dragee contains phenylbutazone and aminophenazone for 125 mg; in bottles of 20 pcs., in the box 1 bottle.

pharmachologic effect

Pharmacological action - anti-inflammatory, antipyretic, analgesic.

Inhibits cyclooxygenase, reduces biosynthesis of PG.

Indication

Acute attacks of inflammatory and degenerative, incl. rheumatic, diseases of the musculoskeletal system, accompanied by severe pain; rheumatoid arthritis; ankylosing spondylitis; acute humeroscapular periarthritis; osteochondrosis, coxarthrosis, gonarthrosis in the exacerbation phase, etc .; iritis, iridocyclitis, febrile conditions.

Contraindications

Hypersensitivity (including to individual components); peptic ulcer of the stomach and duodenum (including in the anamnesis), severe violations of the liver and kidneys; chronic heart failure of IIB and III stage; severe arterial hypertension, hemorrhagic diathesis, impaired hematopoiesis, porphyria; systemic lupus erythematosus; pregnancy, lactation; elderly, child and adolescent (up to 14 years) age.

Side effects

Dizziness, dyspeptic phenomena, erosive and ulcerative lesions of the gastrointestinal mucosa, tachycardia, hemopoiesis, hyperglycemia, edema, skin toxicoallergic manifestations, etc.

Dosing and Administration

Inside, not liquid, squeezed liquid, at the end of a meal or immediately after a meal; the first day - 2 tablets 3 times a day, then no more than 1 dragee 3 times a day. Treatment is carried out in the acute phase of the disease. The duration of the course is not more than one week.

Precautionary measures

Be wary appoint with diabetes. Treatment is recommended only under medical supervision. After the termination of admission, with repeated courses it is necessary to study the cellular composition of the blood.

special instructions

Stains urine in red.

storage Conditions

In a dry place, at a temperature of 15-25 ° C.

Keep out of the reach of children.

Shelf life

5 years.

Do not use after the expiry date printed on the package.